Citigroup
ACOR

Citigroup’s Acorda Therapeutics ACOR Stock Holding History

Citigroup’s Portfolio ACOR Stock Details ACOR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-18
Closed -$272 – 5998
2022
Q4 		$272 Sell
18
-54
-75% -$629 ﹤0.01% 5569
2022
Q3 		$0 Buy
+72
New +$602 ﹤0.01% 6541
2022
Q2 		– Sell
-83
Closed -$3K – 6831
2022
Q1 		$3K Buy
+83
New +$3.26K ﹤0.01% 6015
2021
Q3 		– Sell
-3
Closed – – 6444
2021
Q2 		$0 Buy
+3
New +$262 ﹤0.01% 6505
2021
Q1 		– Sell
-11
Closed -$1.35K – 7684
2020
Q4 		$1K Hold
11
– – ﹤0.01% 7312
2020
Q3 		$1K Sell
11
-18
-62% -$1.36K ﹤0.01% 7410
2020
Q2 		$2K Sell
29
-198
-87% -$20.9K ﹤0.01% 7434
2020
Q1 		$26K Sell
227
-179
-44% -$35.2K ﹤0.01% 6519
2019
Q4 		$100K Buy
406
+143
+54% +$36.1K ﹤0.01% 5778
2019
Q3 		$90K Sell
263
-1,153
-81% -$627K ﹤0.01% 5758
2019
Q2 		$1.3M Buy
1,416
+1,193
+535% +$1.47M ﹤0.01% 3322
2019
Q1 		$356K Sell
223
-1,407
-86% -$2.53M ﹤0.01% 4534
2018
Q4 		$3.05M Buy
1,630
+1,397
+600% +$3.04M ﹤0.01% 2286
2018
Q3 		$549K Buy
233
+114
+96% +$353K ﹤0.01% 4166
2018
Q2 		$410K Buy
119
+108
+982% +$331K ﹤0.01% 4324
2018
Q1 		$32K Buy
11
+4
+57% +$12K ﹤0.01% 6472
2017
Q4 		$18K Sell
7
-591
-99% -$1.68M ﹤0.01% 6789
2017
Q3 		$1.7M Sell
598
-418
-41% -$1.1M ﹤0.01% 2837
2017
Q2 		$2.4M Buy
1,016
+510
+101% +$1.01M ﹤0.01% 2412
2017
Q1 		$1.27M Sell
506
-982
-66% -$2.83M ﹤0.01% 2972
2016
Q4 		$3.36M Buy
1,488
+1,139
+326% +$2.71M ﹤0.01% 2308
2016
Q3 		$874K Buy
349
+209
+149% +$624K ﹤0.01% 3367
2016
Q2 		$427K Sell
140
-122
-47% -$397K ﹤0.01% 3833
2016
Q1 		$833K Buy
262
+226
+628% +$938K ﹤0.01% 3550
2015
Q4 		$188K Sell
36
-110
-75% -$481K ﹤0.01% 4806
2015
Q3 		$465K Buy
146
+103
+240% +$399K ﹤0.01% 3808
2015
Q2 		$171K Sell
43
-2
-4% -$7.73K ﹤0.01% 4557
2015
Q1 		$180K Sell
45
-51
-53% -$234K ﹤0.01% 4617
2014
Q4 		$470K Buy
96
+9
+10% +$38.6K ﹤0.01% 3945
2014
Q3 		$354K Sell
87
-34
-28% -$128K ﹤0.01% 3797
2014
Q2 		$489K Buy
121
+66
+120% +$269K ﹤0.01% 3478
2014
Q1 		$248K Sell
55
-73
-57% -$295K ﹤0.01% 4130
2013
Q4 		$447K Buy
128
+61
+91% +$238K ﹤0.01% 3895
2013
Q3 		$277K Buy
67
+49
+272% +$211K ﹤0.01% 3895
2013
Q2 		$71K Buy
+18
New +$74.1K ﹤0.01% 5129

Other funds holding ACOR

DKCM
Davidson Kempner Capital Management New York $7.33B AUM 56.47% 1-Year Est. Return
DKP
Davidson Kempner Partners New York $5.16B AUM
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TSS
Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

Citigroup's ACOR Position: Q1 2023 in Review

Citigroup sold out of Acorda Therapeutics (ACOR) in Q1 2023, closing a stake of 18 shares — an estimated $272 sold.

Citigroup first reported a position in ACOR in Q2 2013 and held it in 35 quarters. The position peaked at $3.36M in Q4 2016. 29 funds tracked by Wall St. Rank hold ACOR as of Q1 2023.

  • Citigroup reported no remaining Acorda Therapeutics position as of Q1 2023 after selling out during the quarter.
  • Citigroup sold 18 Acorda Therapeutics shares in Q1 2023, an estimated $272.
  • Citigroup first reported a position in Acorda Therapeutics in Q2 2013 and held it in 35 quarters.
  • Citigroup's Acorda Therapeutics position peaked at $3.36M in Q4 2016.
  • 29 funds tracked by Wall St. Rank held Acorda Therapeutics as of Q1 2023.

Based on Citigroup's 13F filing for Q1 2023, filed 11 May 2023.